.

Make Better Decisions

  • Analyze global market entry opportunities
  • Uncover prior art in expired and abandoned patents
  • Drug patents in 130+ countries

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Mallinckrodt
QuintilesIMS
Cerilliant
Teva
Daiichi Sankyo
Chubb
Deloitte
Julphar
Merck
Healthtrust

Generated: December 14, 2017

DrugPatentWatch Database Preview

ENTRESTO Drug Profile

« Back to Dashboard

When do Entresto patents expire, and when can generic versions of Entresto launch?

Entresto is a drug marketed by Novartis Pharms Corp and is included in one NDA. There are six patents protecting this drug.

This drug has eighty-six patent family members in thirty-seven countries and eleven supplementary protection certificates in seven countries.

The generic ingredient in ENTRESTO is sacubitril; valsartan. There are two drug master file entries for this compound. One supplier is listed for this compound. Additional details are available on the sacubitril; valsartan profile page.

US Patents and Regulatory Information

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Patent Submitted Product Substance Delist Req. Exclusivity Expiration
Novartis Pharms CorpENTRESTOsacubitril; valsartanTABLET;ORAL207620-001Jul 7, 2015RXYesNo► Subscribe► Subscribe► SubscribeYY► Subscribe
Novartis Pharms CorpENTRESTOsacubitril; valsartanTABLET;ORAL207620-003Jul 7, 2015RXYesYes► Subscribe► Subscribe► SubscribeY► Subscribe
Novartis Pharms CorpENTRESTOsacubitril; valsartanTABLET;ORAL207620-001Jul 7, 2015RXYesNo► Subscribe► Subscribe► Subscribe► Subscribe
Novartis Pharms CorpENTRESTOsacubitril; valsartanTABLET;ORAL207620-001Jul 7, 2015RXYesNo► Subscribe► Subscribe► SubscribeY► Subscribe
Novartis Pharms CorpENTRESTOsacubitril; valsartanTABLET;ORAL207620-002Jul 7, 2015RXYesNo► Subscribe► Subscribe► Subscribe► Subscribe
Novartis Pharms CorpENTRESTOsacubitril; valsartanTABLET;ORAL207620-003Jul 7, 2015RXYesYes► Subscribe► Subscribe► Subscribe► Subscribe
Novartis Pharms CorpENTRESTOsacubitril; valsartanTABLET;ORAL207620-002Jul 7, 2015RXYesNo► Subscribe► Subscribe► SubscribeYY► Subscribe
Novartis Pharms CorpENTRESTOsacubitril; valsartanTABLET;ORAL207620-003Jul 7, 2015RXYesYes► Subscribe► Subscribe► Subscribe► Subscribe
Novartis Pharms CorpENTRESTOsacubitril; valsartanTABLET;ORAL207620-003Jul 7, 2015RXYesYes► Subscribe► Subscribe► SubscribeY► Subscribe
Novartis Pharms CorpENTRESTOsacubitril; valsartanTABLET;ORAL207620-002Jul 7, 2015RXYesNo► Subscribe► Subscribe► Subscribe► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

International Patent Family for Tradename: ENTRESTO

Country Document Number Estimated Expiration
Hong Kong1175465► Subscribe
MexicoPA04006917► Subscribe
New Zealand600626► Subscribe
China101098689► Subscribe
Japan2011207898► Subscribe
South Korea20130116381► Subscribe
Malaysia145462► Subscribe
Japan4820056► Subscribe
Norway2016008► Subscribe
China102702119► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

Supplementary Protection Certificates for Tradename: ENTRESTO

Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
074Luxembourg► SubscribePRODUCT NAME: SACUBITRIL/VALSARTAN, Y COMPRIS LES SELS PHARMACEUTIQUEMENT ACCEPTABLES DE CELUI-CI; FIRST REGISTRATION DATE: 20151123
2016 00022Denmark► SubscribePRODUCT NAME: SACUBITRIL/VALSARTAN, HERUNDER FARMACEUTISK ACCEPTABLE SALTE DERAF; REG. NO/DATE: EU/1/15/1058 (C(2015)8288) 20151123
2016000037Germany► SubscribePRODUCT NAME: SACUBITRIL/VALSARTAN, EINSCHLIESSLICH PHARMAZEUTISCH ANNEHMBARER SALZE DAVON; REGISTRATION NO/DATE: EU/1/15/1058 20151119
2016 00023Denmark► SubscribePRODUCT NAME: SACUBITRIL/VALSARTAN SOM SACUBITRIL-VALSARTAN-NATRIUMSALTKOMPLEKS; REG. NO/DATE: EU/1/15/1058 (C(2015)8288) 20151123
0810Netherlands► SubscribePRODUCT NAME: SACUBITRIL/VALSARTAN, ALS HET SACUBITRIL VALSARTAN NATRIUMZOUTCOMPLEX, IE. TRINATRIURA (3-((LS,3R)-L-BIFENYL-4-YLMETHYL-3-ETHOXYCARBONYL-L-BUTYLCARBAMOYL)PROPIONAAT-(S)-3'-ETHYL-2'-(PENTANOYL(2"-(TETRAZOL-5-YLAAT)BIFENYL-4'-YLMETHYL)AMINO)BUTYRAAT) HEMIPENTAHYDRAAT; REGISTRATION NO/DATE: EU/1/15/1058 (C(2015) 8288) 20151123
2016017Lithuania► SubscribePRODUCT NAME: SAKUBITRILAS/VALSARTANAS; REGISTRATION NO/DATE: EU/1/15/1058 20151119
90021-9Sweden► SubscribePRODUCT NAME: SACUBITRIL AND VALSARTAN, INCLUDING PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF.; REG. NO/DATE: EU/1/15/1058 20151123
0811Netherlands► SubscribePRODUCT NAME: SACUBITRIL/VALSARTAN, MET INBEGRIP VAN FARMACEUTISCH AANVAARDBARE ZOUTEN DAARVAN; REGISTRATION NO/DATE: EU/1/15/1058 (C(2015) 8288) 20151123
2016000038Germany► SubscribePRODUCT NAME: SACUBITRIL/VALSARTAN, ALS SACUBITRIL VALSARTAN NATRIUM SALZKOMPLEX, D.H. TRINATRIUM-(3-((1 S,3R)-1-BIPHENYL-4-YLMETHYL-3-ETHOXYCARBONYL-1-BUTYLCARBAMOYL)PROPIONAT-(S)-3'-METHYL-2'-(PENTANOYL-(2"-(TETRAZOL-5-YLAT)BIPHENYL-4'-YLMETHYL)AMINO)BUTYRAT)-HEMIPENTAHYDRAT.; REGISTRATION NO/DATE: EU/1/15/1058 20151119
/2016Austria► SubscribePRODUCT NAME: SACUBITRIL/VALSARTAN, EINSCHLIESSLICH PHARMAZEUTISCH ANNEHMBARE SALZE DAVON; REGISTRATION NO/DATE: EU/1/15/1058 20151119
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

« Back to Dashboard

For more information try a trial or see the plans and pricing

Serving leading biopharmaceutical companies globally:

Queensland Health
Colorcon
AstraZeneca
Covington
QuintilesIMS
Boehringer Ingelheim
Teva
Baxter
Julphar
Merck

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:

botpot